HSPA5 and cancer: However, the opposite effect is observed in patients treated with doxorubicin and cyclophosphamide, followed by taxane (paclitaxel or docetaxel) on a clinical trial, where GRP78-positive staining predicts a better recurrence-free survival.114 These results underline the possibility of use combined anticancer drugs to overcome cancer resistance (Figure 3).